tiprankstipranks
Advertisement
Advertisement
Clear Street sees buying opportunity for Beam Therapeutics after study update
PremiumThe FlyClear Street sees buying opportunity for Beam Therapeutics after study update
2M ago
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
Premium
Ratings
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
2M ago
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
Premium
The Fly
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
2M ago
Beam Therapeutics price target raised to $65 from $57 at Wedbush
PremiumThe FlyBeam Therapeutics price target raised to $65 from $57 at Wedbush
3M ago
Beam Therapeutics price target raised to $75 from $74 at Canaccord
Premium
The Fly
Beam Therapeutics price target raised to $75 from $74 at Canaccord
3M ago
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
Premium
Ratings
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100